Clinical Report: Alcon Announces FDA Approval of Tryptyr for DED

Overview

Alcon's Tryptyr (acoltremon ophthalmic solution) 0.003% has received FDA approval for treating dry eye disease (DED), demonstrating rapid tear production as early as Day 1. In pivotal phase 3 trials, Tryptyr showed significant efficacy compared to vehicle, with up to four times more patients achieving a notable increase in natural tear production.

Background

Dry eye disease (DED) is a multifactorial condition characterized by a deficiency in natural tears, leading to discomfort and potential damage to the ocular surface. Traditional treatments often have limitations such as slow onset and poor patient satisfaction. The approval of Tryptyr represents a significant advancement in DED management, offering a new mechanism of action that targets corneal sensory nerves to enhance tear production.

Data Highlights

Key Findings

• Tryptyr is a first-in-class TRPM8 receptor agonist approved for DED treatment.
• In phase 3 trials, Tryptyr demonstrated a significant increase in natural tear production compared to vehicle.
• Patients experienced statistically significant tear production increases as early as Day 1.
• Tryptyr is administered as one drop in each eye, twice daily, in preservative-free single-dose vials.
• The most common adverse reaction reported was instillation-site pain.

Clinical Implications

The approval of Tryptyr provides clinicians with a new treatment option that may improve patient outcomes in DED management. Its rapid onset of action and unique mechanism of action may enhance patient satisfaction and adherence to treatment.

Conclusion

Tryptyr's FDA approval marks a significant milestone in the treatment of dry eye disease, offering a novel approach to stimulate natural tear production and improve patient quality of life.

References

1. Optometric Management, 2025 -- FDA Approves Alcons TRYPTYR for Dry Eye Disease
2. Contact Lens Spectrum, 2025 -- FDA Approves Alcons Tryptyr for Dry Eye Disease
3. Ophthalmology Management, 2025 -- The Latest News in Ophthalmology
4. FDA, Drug Trials Snapshot: TRYPTYR
5. eyecare business — Retail Tech: Alcon, Coburn Technologies, and Hoya
6. FDA Approves Alcon’s TRYPTYR for Dry Eye Disease
7. FDA Approves Alcon’s Tryptyr for Dry Eye Disease
8. Drug Trials Snapshot: TRYPTYR | FDA
9. Efficacy and safety of transient receptor potential channel modulators for dry eye: A systematic review and meta-analysis - ScienceDirect